loading...| Preferred Name |
Ticagrelor |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C76404 |
| Accepted_Therapeutic_Use_For |
Acute Coronary Syndrome |
| CAS_Registry |
274693-27-5 |
| Chemical_Formula |
C23H28F2N6O4S |
| code |
C76404 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923 |
| Contributing_Source |
CTRP FDA |
| DEFINITION |
An orally bioavailable cyclopentyltriazolopyrimidine, with antiplatelet activity. Upon oral administration, ticagrelor and its major metabolite targets and reversibly binds to the platelet adenosine diphosphate (ADP) P2Y12 receptor (P2Y12R) at a site distinct from that of the endogenous agonist ADP. This blocks the platelet signaling pathway, thereby inhibiting the activation of the glycoprotein complex GPIIb/IIIa, fibrinogen binding to platelets and platelet adhesion and aggregation. |
| Display_Name |
Ticagrelor |
| FDA_UNII_Code |
GLH0314RVC |
| FULL_SYN |
Ticalog Brilinta Ticagrelor AR-C126532XX TICAGRELOR (1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol Thioxlant-6C Brilique AZD6140 |
| label |
Ticagrelor |
| Legacy Concept Name |
Ticagrelor |
| Preferred_Name |
Ticagrelor |
| prefixIRI |
Thesaurus:C76404 |
| prefLabel |
Ticagrelor |
| Semantic_Type |
Pharmacologic Substance |
| UMLS_CUI |
C1999375 |
| subClassOf |